home · filing · 0001213900-25-031875
8-K/A filed April 15, 2025, 7:59 PM ET
ticker APTN
CIK 0001938571
other material
confidence high
sentiment negative
materiality 0.80
ADAPTIN BIO, INC. (APTN): M&A transaction — Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt
ADAPTIN BIO, INC.
Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.
Cash of only $34K as of Dec 31, 2024; accumulated deficit $4.12M.
Auditor expresses substantial doubt about ability to continue as going concern.
Convertible notes payable of $1.25M and derivative liability of $545K recorded.
Deferred equity issuance costs of $194K reflect planned capital raise; management cites need for additional funding.
Key facts
Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
ADAPTIN BIO, INC. underwent a change of control involving Unite Acquisition 1 Corp..
Action change of control
Counterparty Unite Acquisition 1 Corp.
Exact text from the filing
the completion of the Merger (as defined in the Original Report)
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-25-031875
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.